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Abstract
CCL2 is an inflammatory mediator that is released by tumor cells to activate and direct
immune cell species, especially macrophages, to inflammatory sites within the body. The goal of
this project was to successfully generate knockout the CCL2 ligand gene using a CRISPR/Cas9
complex delivered via lipid mediated transfection. The sgRNA and Cas9 mRNA were introduced
into the cells via lipid-mediated transfection. The cells were incubated for 4 days, before being
analyzed using PCR and gel electrophoresis. We expected to see one band on the first gel and two
bands on the second gel. Two bands appeared on the first gel and 2 bands appeared on the second
gel. This indicates that the target sequence was amplified, but the transfection efficiency was too
low for the enzyme to detect cleavage. We conclude that lipid mediated transfection is an efficient
method for introducing foreign genetic material into CT-26 cells.
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Introduction
Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause
of cancer related deaths in both men and women in the United States1. Colorectal tumors develop
from growths of epithelial colon cells, called polyps, that spontaneously undergo genetic
modifications to become carcinomas. These genetic modifications promote proliferation and
inhibit apoptosis within the polyp. For tumor progression, it is necessary that the
microenvironment promote inflammation and have infiltrative properties2. Treatment for
colorectal cancer depends on the stage. In Stage 0 and Stage I, cancerous cells have not grown
outside the colon wall. The cells are surgically removed, and the patient typically does not need to
undergo chemotherapy. For more advanced stages, II-IV, the cells have grown outside of the
treatment wall and metastasized to other regions of the body. Treatment includes chemotherapy to
shrink tumors around the body. Shrunken tumors are then removed surgically, and more
chemotherapy is performed3.
The downfall of conventional methods of treatment is that they are nonspecific, which then
results in system toxicity, insufficient drug concentration in tumor cells and the development of
tumor cells are that drug resistant4. Chemotherapy drugs inhibit various stages of the cell cycle to
stop cell division and induce apoptosis. In the process, both cancerous and normal cells are killed.
To prevent healthy cells from being affected, new cancer therapies are being developed that are
specific to cancer cells. This method of targeted therapy employs chemical compounds that inhibit
proliferation and metastasis by suppressing specific proteins involved in tumorigenesis5. Side
effects due to off-target delivery are also minimized, which increases the overall effectiveness4.
The class of targeted therapy we are interested in is monoclonal antibody therapy. Monoclonal
antibodies (mABs) can disrupt cancer cells in three ways: inhibiting protein function and
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downstream

signaling,

antibody-dependent

cytotoxicity,

and

complement-dependent

cytotoxicity5.
Tumors often contain a mixture of fibroblasts, epithelial, and immune cells. Macrophages
are the most abundant immune cell present in the microenvironment and are called tumorassociated macrophages (TAMs) when they infiltrate the tumor mass. There are two types of
macrophages: M1 and M2. The M1 phenotype is anti-tumor and pro-inflammatory; it mediates the
destruction of cancerous tissue. In contrast, the M2 phenotype is pro-tumor and anti-inflammatory.
They work on both the tumor microenvironment and tumor cells to promote cell proliferation and
genetic instability, invasion of tumor cells into the surrounding tissue, forming fibrous tissue
deposits, and angiogenesis6. They also produce growth factors and chemical signals, called
chemokines, to strengthen the inflammatory response2.
Chemokines (CKs) are inflammatory mediators that are released by a variety of cells, such
as endothelial and epithelial, to activate and direct more immune cell species to inflammatory sites
within the body. When CKs are secreted by cells, they travel through the body to other tissues,
such as the brain, blood, and colon, that are expressing the receptor protein on the surface of those
tissues. Ligand binding induces G-protein coupled signal transduction pathways that induce
chemotaxis of monocytes7. Chemokine C-C motif ligand 2 (CCL2) is one of the five members of
the monocyte chemoattractant protein (MCP) family. Though other members of the MCP family
are able to signal through the chemokine C-C motif receptor 2 (CCR2) protein, CCL2 has the
highest potency when activating the signaling pathways to induce cells of the monocyte lineage to
the site of inflammation, especially TAMs8. CCL2 is shown to be involved in both early and late
steps in metastasis. Initially, CCL2 guides cancer cell migration when it interacts with the CCR2
receptor. Binding initiates a signaling cascade to express metalloproteinases and induce
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intravasation of cancer cells into the circulation. Extravasation from the circulation occurs when
the cancer cells interact with TAMs, which are highly influenced by CCL2. Later in metastasis,
CCL2 preferentially attracts cancer cells, stimulates their proliferation and enhances their
survival7.
The effects of CCL2 can be prevented by setting up a monoclonal antibody blockade, in
which the anti-CCL2 antibody binds to the CCL2 ligand and prevents it from binding to the CCR2
receptor. However, antibodies are not as specific as was once believed and are able to interact with
other antigens9. In order to study the effects of adding an antibody when its preferred ligand is not
present is to generate a knockout of the ligand gene, add in the antibody, and see if any
promiscuous binding occurs. The ligand gene we eliminated was the CCL2 gene in a CT-26 cell
line, which is a mouse colon carcinoma fibroblast.
To generate a knockout of the CCL2 gene in CT-26 cells, a prokaryotic genomic editing
system was used and delivered via lipid mediated transfection. Clustered Regularly Interspersed
Short Palindromic Repeat (CRISPR) is a section of DNA that includes repeating nucleotide
sequences and spacers between the repeating sequences. The CRISPR system originated in
bacteria and archaea as an RNA-based bacterial adaptive immune system used to modify DNA. It
combines a CRISPR-associated protein 9 (Cas9) with a CRISPR RNA (crRNA) and a
transactivating crRNA (tracrRNA). The two RNA structures combine to form a single-guide RNA
(sgRNA) that attracts the Cas9 protein to the protospacer adjacent motif (PAM) sequence at the
beginning of the cleavage site. The PAM sequence is where the sgRNA and target DNA pairing
occurs and helps mediate the double-stranded DNA cleavage10. When the sgRNA-DNA pairing
has occurred, the Cas9 protein can also bind to the complex and cause a double-stranded break
(DSB) to occur within the target DNA. The DNA is repaired via non-homologous end-joining
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(NHEJ) by recognition of the DSB, bridging the ends of the DNA to promote stability and process
them, and direct ligation of the ends to repair the DSB11. Repairing DNA via NHEJ is more likely
to cause a frameshift mutation, either insertion or deletion, at the cleavage site. The creation of a
mutation is the goal of the Cas9 complex and the Cas9 protein will continue to make DSBs in the
DNA until a mutation occurs during repair10 (Fig 1).

Figure 1. Illustration of how the Cas9 complex causes DNA cleavage.

Since the Cas9 protein and sgRNAs are not natural to mammalian cells they must be
delivered into the cell. Cas9 can either be introduced as mRNA or as an already transcribed,
functional protein. Although both mRNA and protein require assistance getting through the cell
membrane, the protein is bulkier than the mRNA and often has low potential to penetrate the cell
membrane12. The protein is also in an unprotected state and would quickly be cleared by endosomal
proteases or neutralized by antibodies13. Transfecting mRNA is slightly easier and allows for the
Cas9 protein to be transiently expressed, which increases the time that the protein is transcribed
within the cell and minimizes the possibility of off-target genomic modifications since it is only
expressed for a short period of time14.
There are three methods in which foreign material can be delivered into a cell:
electroporation, viral delivery, and transfection15. Electroporation is the use of pulsatile highvoltage electrical currents to cause pores to form within the cell membrane. Cells are suspended
in a buffer solution containing the material that needs to enter the cell, while the electric current is
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applied the material can flow through the pores in the cell membrane. When the electric current
ceases, the pores close and the cell membrane repairs itself16. Although this method is useful for
moving large amounts of foreign material, it is not suitable for all cell types as it can cause stress
to the cells and cytotoxicity16,17. Viral delivery of foreign material can be via retrovirus, lentivirus,
adenovirus, or adeno-associated virus. They also are able to deliver large amounts of foreign
material into the cell at once and have high efficiency rates17. However, the virus can integrate into
the host genome and cause insertional mutagenesis18. There is also potential for the virus to cause
an immunogenic reaction within the cell17.
Genetic material can be transfected into the cell in multiple fashions, but the most common
form is lipid mediated transfection. Nucleic acids, such as Cas9 mRNA and sgRNA, are highly
anionic have difficulty passing through the hydrophobic region of the lipid bilayer16.
Lipofectamine reagents are cationic lipids that encapsulate the genetic material and guide it
through the cell membrane, while protecting them from degradation and escape13,16 (Fig 2).
Although the quantity that can be delivered via lipid mediated transfection is more limited than
other methods, there is less potential for immunogenic reactions, cytotoxicity, and cellular
disruption16.

Lipofectamine

mRNA

mRNA-Cationic
Lipid complex

Cationic lipid guides mRNA
through membrane

Figure 2. Schematic of lipid mediated transfection.

Cas9 protein is fully expressed
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Transfection efficiency is dependent on several factors, including the chemical properties
and mechanism of uptake of the lipid complex, the intracellular delivery route, and the type of cell
being transfected. The cell line we are working with, CT-26, is known to be difficult to transfect.
The uptake of foreign material into the cell happens more slowly in CT-26 cells due to an
overproduction of heavily glycosylated proteins, called mucins19. The mucins act as a physical
barrier and have a tendency to bind to cationic complexes to induce aggregate formation. The
aggregates cause the complexes to have difficulty moving through the cytoplasm and entering the
nucleus. As well as, being easily shunted into endo-lysosomal pathways for degradation19.
To minimize the limitations of CT-26 cells, the medium used to culture the cells did not
contain any serum or antibiotics. Certain serum proteins can inhibit the formation of the RNAlipid complexes and reduce the amount of RNA that enters the cell20. Serum starvation also
synchronizes cells to the G0 phase and ensures that the progress through the cell cycle at the
same rate21. Antibiotics were eliminated from the medium as well as they are known to lower the
transfection efficiency. Removing antibiotics also prevent the cells from becoming cytotoxic due
to the increased permeability of the cell membrane to foreign material20,22.

Materials and Methods
Cell Culture
The CT-26 cell line should be cultured in serum free medium and cultured without
antibiotics to increase the transfection efficiency. Cells should be fed every 3 days and passaged
when they are about 70% confluent to maintain a healthy population. When the 6-well plate is
ready to be prepared, the cells should be counted and seeded to a density of 100,000 cells per well
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with 2 mL of media per well. Incubate the cells at 37 °C and 5% CO2. The well plate will be ready
to use when the cells are approximately 60% confluent.

Preparation of Stock sgRNA Solution
Remove the tube of concentrated sgRNA from the freezer and bring to room temperature.
Centrifuge the tube at 4,000 RCF for 5 minutes. Add 30 µL of 1 TE buffer to create a 100 µM
stock solution, this is equal to 1.3 mg/mL. Vortex the tube to resuspend the gRNA and centrifuge
the tube for 1 minute at 4,000 RCF. Incubate the tube at room temperature for 30 minutes to allow
the sgRNA to dissolve. Use the vortex to thoroughly mix the solution and centrifuge again for 1
minute at 4,000 RCF.

Transfection of CT-26 Cells
In a sterile cell culture fume hood, take out two small centrifuge tubes. Tube 1 will consist
of the Cas9 mRNA/sgRNA solution. The reagents must be added exactly in the order described:
125 µL of Opti-MEM I medium, 2.5 Cas9 µL mRNA nuclease, 1.25 µL sgRNA, and 12.5 µL Cas9
Plus reagent. Remove the tube from the hood and vortex to thoroughly mix. In Tube 2, add 125
µL Opti-MEM I medium and 7.5 µL Lipofectamine CRISPRMAX reagent. Pipette the contents
of Tube 1 into Tube 2, vortex the solution to mix. Incubate the transfection reagent for 15 minutes
at room temperature and add 250 µL of transfection reagent to each well. If the bottom of the well
is not completely covered, add more Opti-MEM I medium until it is. Incubate the cells at 37 °C
and 5% CO2 for 4 days.
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Harvesting and Lysing Transfected Cells
Remove 6-well plate from the incubator. Remove media and wash with 500 µL of PBS.
Add 1 mL of trypsin and incubate at 37 °C and 5% CO2 for five minutes. Check the cells under
the microscope to ensure that they are detached from the bottom of the well. Add 1 mL of OptiMEM I medium and transfer the contents to a centrifuge tube. Centrifuge the cells at 200g for 5
minutes at 4 °C. Remove the supernatant. In a separate tube, mix 288 µL cell lysis buffer with 12
µL of the protein degrader. Add 50 µL of the cell lysis/protein degrader solution to the pellet and
resuspend. The remaining cell lysis/protein degrader solution can be stored at -20 °C. Transfer all
the resuspended pellet into a PCR tube and run the program (Table 1) in a thermal cycler.
Table 1. Cell lysis thermal cycler program.

Temperature
68 C
95 C
4C

Time
15 minutes
10 minutes
Hold

PCR Primer Design
The PCR primers were designed based on the following guidelines from the genomic
cleavage detection kit. Primers must be between 18 and 22 bp long, contain 45-60% guaninecytosine (GC) content, yield amplicons between 400-500 bp long, and have melting temperature
™ greater than 55 ºC. The target sequence cannot be in the middle of the amplicon, to ensure that
two distinct bands would form. Online software from Primer3Plus was used to design the PCR
primers. We tested two primers. For the first primer (Fig 3A) the forward primer sequence is
cccactcacctgctgctact (20 bp, Tm 60.5, GC 60%) and the reverse primer sequence is
aaaatggatccacaccttgc (20 bp, Tm 59.8, GC 45%). With this primer, the total amplicon length is
470 base pairs (bp) and after cleavage detection we expect two bands of lengths of approximately
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40 and 430. The forward primer sequence for the second primer (Fig 3b) is cccactcacctgctgctact
(20 bp, Tm 60.5, GC 60%) and the reverse primer sequence is atggatccacaccttgcatt (20 bp, Tm
60.2, GC 45%). With the second primer we expect a total amplicon size of 473 bp and after
cleavage detection the two bands should be approximately 41 bp and 434 bp. The location of the
primers in relation to the target sequence is shown below (Fig 3).
B

A

Figure 3. Gene sequence for CCL2 and locations of the primers in relation to the target sequence (A) primer 1 and
(B) primer 2.

DNA Amplification via PCR
After the program is completed, vortex the cell lysate. In a new PCR tube add the reagents
in the order as listed: 2 µL cell lysate, 10 µL SYBR Green dye, 1 µL 10 µM Forward/Reverse
primer mix, 25 µL AmpliTaq Gold360 Master Mix, and 12 µL water as provided by the kit. The
total volume in the PCR tube will be 50 µL. The PCR reaction will be performed as specified in
Table 2.
Table 2. PCR description for amplification of the target DNA sequence.

Stage
Enzyme Activation
Denature
Anneal
Extend
Final Extension
Hold

Temperature
95 C
95 C
57 C
72 C
72 C
4C

Time
10 minutes
30 seconds
30 seconds
30 seconds
7 minutes
Hold

Cycles
1X
40 X

1X
1X
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Verification of the PCR Product
Remove an agarose gel tray from the package and place in the E-Gel iBase Power System.
Load one well with 20 µL with a 1 kB DNA ladder. In a PCR tube combine 3 µL of the PCR
product with 7 µL loading buffer and 10 µL water. Vortex to mix and load the entire sample onto
the gel. Run the gel for 30 minutes. View the product with a UV transilluminator. It is expected
that one band that is approximately 470 bp long is seen.

Denaturing and Re-annealing of DNA
The PCR product will be denatured, and fragments are re-annealed with and without indels
to form heterogeneous DNA duplexes. In a new PCR tube, combine 2 µL of the PCR product with
1 µL Detection Reaction Buffer. Add 6 µL of water and briefly centrifuge to eliminate bubbles.
The reannealing reaction will take place as described in Table 3.
Table 3. PCR description for denaturing and re-annealing of amplicons to form heterogeneous DNA duplexes.

Stage
1
2
3
4

Temperature
95 C
95-85 C
85-25 C
4C

Time
5 minutes
-

Temp/Time
-2 C/sec
-0.1 C/sec
Hold

Enzyme Digestion
The detection enzyme identifies the heterogenous DNA duplexes that are formed during
the re-annealing process and cleaves that ones that contain indels. If there are no indels, then the
detection enzyme will not cleave the DNA. Add 1 µL of the detection enzyme to the tube and
incubate at 37 ºC and 5% CO2 for one hour. After incubating, vortex the solution and briefly
centrifuge at 4,000 RCF for one minute.
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Figure 4. Schematic describing how the cleavage detection enzyme cleaves DNA. After the DNA has been denatured
and re-annealed, the DNA forms heterogeneous duplexes (mismatches). The enzyme detects the mismatches and
cleaves the DNA.

Cleavage Detection Analysis
Dilute the sample with 10 µL water. Obtain a new agarose gel tray and place in the E-Gel
iBase Power tray. In one well, add 10 µL of 1 kB DNA ladder. Add all 20 µL of the sample to a
separate well. Run the gel for 30 minutes and view under a UV transilluminator. It is expected that
two distinct bands will be seen on the gel as described in the PCR primer design section.

Results
Verification of PCR Amplification

Figure 5. Gel electrophoresis image verifying the size of the PCR amplicons.
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Figure 5 shows the results of the PCR amplification of the gene sequence. From this
reaction it was expected that a single distinct band of approximately 470 bp would be seen, the
expected value is shown by the black arrow in the figure. Lane 5 contained the 50 bp DNA marker.
Lane 6 is color coded green and contained primer one, which showed two faint bands of
approximately 375 and 80 base pairs long. Lane 7 is color coded purple and contained primer two,
which showed two bands of approximately 450 and 100 base pairs long. It is unclear exactly what
caused additional bands to appear, but there are several possibilities.
First possibility is that the program used to design the PCR primers did not search any
genetic databases to check that the primer sequence was unique to the intended target sequence.
There could have been other sequences on a different gene that could have been similar enough to
the intended target and caused binding to occur23. The second possibility is that the GC content of
the forward sequences was too high. If the GC content is too high, the primer may bind nonspecifically to other sections of DNA. It is suggested that the optimal GC content percentage
should be as close to 45% as possible. Both forward primers had GC contents of 60%, which was
the maximum value as stated by the guidelines in the genomic cleavage detection kit. The third
possibility is that the ramping speed of the thermal cycler was too slow and caused non-specific
band formation. When the ramping speed is too slow, it allows more time for spontaneous
annealing and binding to occur24.
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Cleavage Detection Enzyme Analysis

Figure 6. Gel electrophoresis image of PCR amplicons after the cleavage detection enzyme has been applied to the samples.

Figure 6 shows the number of bands after the detection enzyme was applied to the
amplified DNA. It was expected that two distinct bands of approximately 30 and 440 bp would be
seen. Lane 5 contains the 50 bp DNA ladder. Lane 6 is color coded green and contained primer
one. Lane 7 is color coded purple and contained primer 2. For both lane 6 and 7 the bands are in
the same positions as they were before the cleavage detection enzyme was added and appear to be
fainter. This indicates that no cleavage occurred.
If a frameshift mutation had occurred from the CRISPR/Cas9 complex, the enzyme would
have cleaved the DNA. Not obtaining the two expected bands is shows that the CRISPR/Cas9
complex was unable to reach the nucleus and make incisions in the DNA to induce a CCL2 gene
knockout25. This is most likely due to mucin overproduction within CT-26 cells that caused lipid
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aggregation and prevented the CRISPR complex from reaching the nucleus. Mucins tend to
gravitate towards the surface of the cell, so when the lipid complexes attempt to enter the cell they
immediately come into contact with the mucins. The mucins cause aggregation and the aggregates
are then shunted into endosomal pathways to be removed from the cells as waste products. The
mRNA and sgRNA associated with the lipofectamine is also shunted into the pathway19. Even if
there was a small amount of the CRISPR complex that made it to the nucleus to induce a knockout,
it would not be sufficient enough for two distinct bands to appear.

Discussion
Conclusions
We have shown that lipid mediated transfection is an inefficient method in which to
transfect a CRISPR/Cas9 complex to induce a gene knockout. A more efficient method for
transfecting CT-26 cells needs to be found before the effects of unknown antibodies can be
determined. Since CT-26 cells are known to have an overproduction of mucins that cause lipid
aggregate formation, it would be better to use an electroporator to move the genetic material inside
of the cell. An electroporator machine uses pulsatile high-voltage electrical currents to cause pores
to form within the cell membrane while the cells are suspended in a buffer solution that contains
the genetic material that needs to be transfected into the cell16. This cell line tends to be hardier
than other cells and would most likely be able to withstand the harsh conditions of the
electroporator19.
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Future Directions
However, electroporation machines are expensive to buy and maintain. A more costeffective method would be to abandon the CT-26 cells in favor of an easier to transfect cell line.
A cell line that is known to be easy to transfect is the SK-BR3, which is a human breast
adenocarcinoma cell line. The SK-BR3 cells do not over produce mucins, so the rate of
internalization of the transfected material is much higher than that of the CT-26 cells19.
Transfection is never one hundred percent efficient. There will always be some cells that
remain non-transfected within the well-plate. When a method of transfection has been established
and upon verification shows that at least 60% of the cells do not have the CCL2 gene, it can then
be considered successful. The knockout cells will need to be separated from the wild type cells.
This should be done using flow cytometry without fluorescence. The addition of fluorescent dyes
is also not completely efficient, and it is likely that the dye could tag a wild type cell. The exact
methods of how to sort for the transfected cells will need to be determined after a successful
knockout is generated.
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